NEW YORK, NY / ACCESSWIRE / September 29, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SMFR Shareholders Click Here: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32245&wire=1
MDT Shareholders Click Here: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32245&wire=1
YSG Shareholders Click Here: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32245&wire=1

* ADDITIONAL INFORMATION BELOW *

Sema4 Holdings, Corp. (NASDAQ:SMFR)

SMFR Lawsuit on behalf of: investors who purchased March 14, 2022 - August 15, 2022
Lead Plaintiff Deadline : November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sema4-lawsuit-loss-submission-form?prid=32245&wire=1

According to the filed complaint, during the class period, Sema4 Holdings, Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) there was a significant risk that Sema4 would reverse a material amount of previously recognized revenue that it could not recoup from third party payors; (2) the Company was experiencing declining selling prices for its reproductive health segment; (3) as a result of the foregoing, Sema4's financial results would be adversely affected; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Medtronic plc (NYSE:MDT)

This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.
Lead Plaintiff Deadline : November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=32245&wire=1

According to the filed complaint, (1) Medtronic's product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company's misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company's need to improve its quality control systems, would negatively affect the Company's financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Yatsen Holding Limited (NYSE:YSG)

This lawsuit is on behalf of a class consisting of all persons and entities who purchased Yatsen Holding Limited American Depository Shares ('ADS') between November 19, 2020 and March 10, 2022 or acquired Yatsen ADS pursuant or traceable to documents issued in connection with Yatsen's November 2020 initial public stock offering.
Lead Plaintiff Deadline : November 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32245&wire=1

According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering ('IPO'), Yatsen and the other named defendants misled investors into believing that Yatsen's most significant brands, Perfect Diary and Little Ondine, were thriving, thereby driving Yatsen's 'healthy' top-line growth at the time of its IPO and quarter after quarter thereafter. In truth, however, cosmetic and skincare sales of Perfect Diary and Little Ondine products were declining in the period leading up to (and including at the time of) the IPO and throughout 2021. Moreover, as the truth about Yatsen's business reached the market, the value of the Company's shares declined dramatically, causing Yatsen investors to suffer significant damages.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP